Market Cap 302.10M
Revenue (ttm) 30,000.00
Net Income (ttm) -51.63M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -172,100.01%
Debt to Equity Ratio 0.00
Volume 3,894,000
Avg Vol 1,150,238
Day's Range N/A - N/A
Shares Out 147.37M
Stochastic %K 100%
Beta 2.48
Analysts Strong Sell
Price Target $8.29

Company Profile

InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology in Germany and the United States. The company's C5a is an inflammatory mediator to treat variety of autoimmune and other inflammatory diseases. Its lead product candidate is vilobelimab, a a first-in-class monoclonal anti-human complement factor C5a antibody, which is in Phase 3 clinical trial for the treatment for patients suffering from early septic organ dysfunction, biological pro...

Industry: Biotechnology
Sector: Healthcare
Phone: 49 3641 508 180
Address:
Winzerlaer Str. 2, Jena, Germany
FlowerInTheCellar
FlowerInTheCellar Aug. 26 at 2:44 PM
$IFRX Interesting date for the IFRX community: At the 10th Complement-Based Drug Development Summit in Boston (December 8–10, 2026), Niels Riedemann, CEO of InflaRx, is scheduled to present on Izicopan on Wednesday, December 9, at 9:30 AM Boston time (3:30 PM German time). The title is “Izicopan: A Best-in-Class Profile C5aR Inhibitor with Potential in ANCA Associated Vasculitis & Beyond”; according to the organizers, the presentation will cover AAV and other complement-mediated diseases, the differentiation of Izicopan, and the future role of targeted complement inhibition in renal, inflammatory and immune-mediated indications. Source: 10th Complement-Based Drug Development Summit, Boston, December 9, 2026 – Niels Riedemann / InflaRx.
0 · Reply
JerzeyDevil
JerzeyDevil Aug. 26 at 2:03 PM
$IFRX 🙏
1 · Reply
Barkingdogs
Barkingdogs Aug. 26 at 1:58 PM
$IFRX itsa buy they have the goods to go the distance watch for the big short covering run.
0 · Reply
dogDazeSummer
dogDazeSummer Aug. 26 at 1:16 PM
$IFRX Reminder biggest shareholder changed names. Suvretta now Montanova - they own 22.9m shares. “In July 2026, the hedge fund Suvretta Capital Management officially changed its corporate registration name to Montanova Capital.” Since they just crossed the 15% thereshold, are they considered “an insider” thus reducing float? I show float dropping down from ~105m to 93m. Either way, they’re never selling until liquidity event. **What other reasons would cause float to be 93m w insiders only having ~5%? Fidelity became a 5% holder on 06 Aug, so that explains no short covering occurred (now in 5 Fidelity funds). They were buyers through 05AUG & likely sttill are. With 147m total oustanding, a float of ~93m and institutional ownership of ~94m, 15m known retail - plus ~10m short —-cld we begin to set off some alarm bells? Note 2 x yest there were no shares to borrow - now 500k down from 2m+ earlier in week. **68 high name funds own 64% of float OR 110% (plus short)?
0 · Reply
levystrauss
levystrauss Aug. 26 at 9:07 AM
$IFRX 🤷‍♂️
1 · Reply
Sterphanise
Sterphanise Aug. 26 at 6:05 AM
$IFRX Another slight increase in short positions between 07/31/2026 and 08/14/2026, while the shareprice was climbing from ~1,7$ to ~2$ in the same timeframe.
0 · Reply
Sesamo
Sesamo Aug. 26 at 3:12 AM
$IFRX Nice volume today 🤞🤞🤞
0 · Reply
NYBomba
NYBomba Aug. 25 at 9:50 PM
$IFRX - RIP 👩 Dolly Parton ❤️‍🩹☮️
0 · Reply
createrrit
createrrit Aug. 25 at 9:43 PM
$IFRX dear stock gods, please let this breakout be the real thing. We kindly offer Holden as a sacrificial lamb for this to materialize.
1 · Reply
Barkingdogs
Barkingdogs Aug. 25 at 9:07 PM
$IFRX significant institutional buyer recently appeared in IFRX. The most notable one is Spruce Street Capital LP. Its latest Form 13F shows a new position of 5,352,198 IFRX shares, representing about 3.63% of InflaRx. � MarketBeat A few other recent institutional moves are also interesting: Spruce Street Capital: +5.35 million shares — new position Verde Serviços Internacionais: +251,000 shares in Q2 Marshall Wace: +274,324 shares in Q1 Cubist Systematic Strategies: increased its position by about 34% in Q1 Overall, 13 institutions increased positions, while 16 reduced them in the latest reporting period. � Quiver Quantitative There are currently 68 institutional holders reporting IFRX positions, totaling roughly 94.5 million shares. �🤑🤑🤑
0 · Reply
Latest News on IFRX
InflaRx Earnings release: Q2 2026

Aug 6, 2026, 9:30 AM EDT - 20 days ago

InflaRx Earnings release: Q2 2026


InflaRx files $250M mixed securities shelf

2026-08-06T13:26:42.000Z - 20 days ago

InflaRx files $250M mixed securities shelf


InflaRx Registration statement: Registration filing

Aug 6, 2026, 8:00 AM EDT - 20 days ago

InflaRx Registration statement: Registration filing


InflaRx to Report Second Quarter 2026 Results on August 6, 2026

Jul 30, 2026, 7:30 AM EDT - 27 days ago

InflaRx to Report Second Quarter 2026 Results on August 6, 2026


InflaRx upgraded to Strong Buy from Outperform at Raymond James

2026-05-13T12:32:38.000Z - 3 months ago

InflaRx upgraded to Strong Buy from Outperform at Raymond James


InflaRx price target raised to $8 from $6 at H.C. Wainwright

2026-05-11T18:30:06.000Z - 3 months ago

InflaRx price target raised to $8 from $6 at H.C. Wainwright


InflaRx Transcript: Investor update

May 8, 2026, 8:30 AM EDT - 3 months ago

InflaRx Transcript: Investor update


InflaRx Press release: Investor update

May 8, 2026, 8:30 AM EDT - 3 months ago

InflaRx Press release: Investor update


InflaRx Slides: Investor update

May 8, 2026, 8:30 AM EDT - 3 months ago

InflaRx Slides: Investor update


InflaRx to develop izicopan in AAV

2026-05-07T03:51:29.000Z - 3 months ago

InflaRx to develop izicopan in AAV


InflaRx announces new izicopan pre-clinical data

2026-05-04T12:09:26.000Z - 4 months ago

InflaRx announces new izicopan pre-clinical data


InflaRx to Report First Quarter 2026 Results on May 7, 2026

May 1, 2026, 7:30 AM EDT - 4 months ago

InflaRx to Report First Quarter 2026 Results on May 7, 2026


InflaRx assumed with an Outperform at Oppenheimer

2026-04-24T11:41:38.000Z - 4 months ago

InflaRx assumed with an Outperform at Oppenheimer


InflaRx announces new izicopan in vitro findings

2026-04-09T11:54:44.000Z - 4 months ago

InflaRx announces new izicopan in vitro findings


InflaRx presents vilobelimab data

2026-03-30T12:10:23.000Z - 5 months ago

InflaRx presents vilobelimab data


InflaRx price target lowered to $14 from $22 at Guggenheim

2026-03-20T11:20:14.000Z - 5 months ago

InflaRx price target lowered to $14 from $22 at Guggenheim


InflaRx Annual report: Q4 2025

Mar 19, 2026, 9:30 AM EDT - 5 months ago

InflaRx Annual report: Q4 2025


InflaRx Earnings release: Q4 2025

Mar 19, 2026, 9:30 AM EDT - 5 months ago

InflaRx Earnings release: Q4 2025


InflaRx reports FY25 EPS (EUR 0.68) vs. (EUR 0.78) last year

2026-03-19T11:35:54.000Z - 5 months ago

InflaRx reports FY25 EPS (EUR 0.68) vs. (EUR 0.78) last year


InflaRx to Report Full Year 2025 Results on March 19, 2026

Mar 12, 2026, 7:30 AM EDT - 5 months ago

InflaRx to Report Full Year 2025 Results on March 19, 2026


InflaRx Transcript: Leerink Global Healthcare Conference 2026

Mar 9, 2026, 9:20 AM EDT - 6 months ago

InflaRx Transcript: Leerink Global Healthcare Conference 2026


InflaRx downgraded to Market Perform from Outperform at Leerink

2025-12-03T11:53:16.000Z - 9 months ago

InflaRx downgraded to Market Perform from Outperform at Leerink


InflaRx downgraded to Market Perform from Outperform at Leerink

2025-12-03T11:16:16.000Z - 9 months ago

InflaRx downgraded to Market Perform from Outperform at Leerink


InflaRx price target raised to $8 from $3 at Cantor Fitzgerald

2025-11-11T11:20:32.000Z - 10 months ago

InflaRx price target raised to $8 from $3 at Cantor Fitzgerald


InflaRx price target raised to $9 from $2 at Raymond James

2025-11-11T11:16:27.000Z - 10 months ago

InflaRx price target raised to $9 from $2 at Raymond James


InflaRx price target raised to $7 from $3 at Oppenheimer

2025-11-11T11:15:24.000Z - 10 months ago

InflaRx price target raised to $7 from $3 at Oppenheimer


InflaRx Earnings release: Q3 2025

Nov 10, 2025, 4:00 PM EST - 10 months ago

InflaRx Earnings release: Q3 2025


InflaRx Transcript: Status Update

Nov 10, 2025, 8:00 AM EST - 10 months ago

InflaRx Transcript: Status Update


InflaRx Press release: Status Update

Nov 10, 2025, 8:00 AM EST - 10 months ago

InflaRx Press release: Status Update


InflaRx Slides: Status Update

Nov 10, 2025, 8:00 AM EST - 10 months ago

InflaRx Slides: Status Update


InflaRx Transcript: Cantor Global Healthcare Conference 2025

Sep 4, 2025, 9:10 AM EDT - 1 year ago

InflaRx Transcript: Cantor Global Healthcare Conference 2025


InflaRx Earnings release: Q2 2025

Aug 7, 2025, 7:00 AM EDT - 1 year ago

InflaRx Earnings release: Q2 2025


InflaRx to Participate in Upcoming Investor Conferences

May 22, 2025, 7:30 AM EDT - 1 year ago

InflaRx to Participate in Upcoming Investor Conferences


InflaRx Earnings release: Q1 2025

May 7, 2025, 9:30 AM EDT - 1 year ago

InflaRx Earnings release: Q1 2025


InflaRx to Report First Quarter 2025 Results on May 7, 2025

Apr 30, 2025, 7:30 AM EDT - 1 year ago

InflaRx to Report First Quarter 2025 Results on May 7, 2025


InflaRx Earnings release: Q4 2024

Mar 20, 2025, 9:30 AM EDT - 1 year ago

InflaRx Earnings release: Q4 2024


InflaRx Annual report: Q4 2024

Mar 20, 2025, 9:30 AM EDT - 1 year ago

InflaRx Annual report: Q4 2024


InflaRx Earnings release: Q3 2024

Nov 8, 2024, 9:30 AM EST - 1 year ago

InflaRx Earnings release: Q3 2024


InflaRx Announces Participation in September Investor Events

Aug 27, 2024, 7:30 AM EDT - 2 years ago

InflaRx Announces Participation in September Investor Events


InflaRx Earnings release: Q2 2024

Aug 8, 2024, 9:30 AM EDT - 2 years ago

InflaRx Earnings release: Q2 2024


FlowerInTheCellar
FlowerInTheCellar Aug. 26 at 2:44 PM
$IFRX Interesting date for the IFRX community: At the 10th Complement-Based Drug Development Summit in Boston (December 8–10, 2026), Niels Riedemann, CEO of InflaRx, is scheduled to present on Izicopan on Wednesday, December 9, at 9:30 AM Boston time (3:30 PM German time). The title is “Izicopan: A Best-in-Class Profile C5aR Inhibitor with Potential in ANCA Associated Vasculitis & Beyond”; according to the organizers, the presentation will cover AAV and other complement-mediated diseases, the differentiation of Izicopan, and the future role of targeted complement inhibition in renal, inflammatory and immune-mediated indications. Source: 10th Complement-Based Drug Development Summit, Boston, December 9, 2026 – Niels Riedemann / InflaRx.
0 · Reply
JerzeyDevil
JerzeyDevil Aug. 26 at 2:03 PM
$IFRX 🙏
1 · Reply
Barkingdogs
Barkingdogs Aug. 26 at 1:58 PM
$IFRX itsa buy they have the goods to go the distance watch for the big short covering run.
0 · Reply
dogDazeSummer
dogDazeSummer Aug. 26 at 1:16 PM
$IFRX Reminder biggest shareholder changed names. Suvretta now Montanova - they own 22.9m shares. “In July 2026, the hedge fund Suvretta Capital Management officially changed its corporate registration name to Montanova Capital.” Since they just crossed the 15% thereshold, are they considered “an insider” thus reducing float? I show float dropping down from ~105m to 93m. Either way, they’re never selling until liquidity event. **What other reasons would cause float to be 93m w insiders only having ~5%? Fidelity became a 5% holder on 06 Aug, so that explains no short covering occurred (now in 5 Fidelity funds). They were buyers through 05AUG & likely sttill are. With 147m total oustanding, a float of ~93m and institutional ownership of ~94m, 15m known retail - plus ~10m short —-cld we begin to set off some alarm bells? Note 2 x yest there were no shares to borrow - now 500k down from 2m+ earlier in week. **68 high name funds own 64% of float OR 110% (plus short)?
0 · Reply
levystrauss
levystrauss Aug. 26 at 9:07 AM
$IFRX 🤷‍♂️
1 · Reply
Sterphanise
Sterphanise Aug. 26 at 6:05 AM
$IFRX Another slight increase in short positions between 07/31/2026 and 08/14/2026, while the shareprice was climbing from ~1,7$ to ~2$ in the same timeframe.
0 · Reply
Sesamo
Sesamo Aug. 26 at 3:12 AM
$IFRX Nice volume today 🤞🤞🤞
0 · Reply
NYBomba
NYBomba Aug. 25 at 9:50 PM
$IFRX - RIP 👩 Dolly Parton ❤️‍🩹☮️
0 · Reply
createrrit
createrrit Aug. 25 at 9:43 PM
$IFRX dear stock gods, please let this breakout be the real thing. We kindly offer Holden as a sacrificial lamb for this to materialize.
1 · Reply
Barkingdogs
Barkingdogs Aug. 25 at 9:07 PM
$IFRX significant institutional buyer recently appeared in IFRX. The most notable one is Spruce Street Capital LP. Its latest Form 13F shows a new position of 5,352,198 IFRX shares, representing about 3.63% of InflaRx. � MarketBeat A few other recent institutional moves are also interesting: Spruce Street Capital: +5.35 million shares — new position Verde Serviços Internacionais: +251,000 shares in Q2 Marshall Wace: +274,324 shares in Q1 Cubist Systematic Strategies: increased its position by about 34% in Q1 Overall, 13 institutions increased positions, while 16 reduced them in the latest reporting period. � Quiver Quantitative There are currently 68 institutional holders reporting IFRX positions, totaling roughly 94.5 million shares. �🤑🤑🤑
0 · Reply
Barkingdogs
Barkingdogs Aug. 25 at 8:52 PM
$IFRX I'd rate the situation: Factor Assessment Short interest 🟢 Very favorable Days to cover 🟢 Very favorable Today's volume 🟢 Very favorable Today's price action 🟢 Very favorable New fundamental news today 🟡 Not apparent Evidence shorts are covering 🟡 Not confirmed yet Overall squeeze potential 7.5/10 The levels I'd watch tomorrow $2.40–$2.50: First important test. If IFRX can push through this area on increasing volume, I would become considerably more bullish on a squeeze. $2.75: Very important. A move toward the old $2.95 52-week high could force substantially more attention from momentum traders and potentially shorts. � Finviz $2.95–$3.00: This is the big one. A clean break above $3 could change the character of the trade. If it breaks $3 with very heavy volume, I'd start looking at $4$5 as realistic squeeze targets, rather than assuming $3 is the ceiling.
2 · Reply
Coffebreak91
Coffebreak91 Aug. 25 at 8:41 PM
$IFRX what’s happening today ?
0 · Reply
NYBomba
NYBomba Aug. 25 at 8:07 PM
$IFRX - and that’s our double bottom breakout … 💕💥☮️
0 · Reply
Holten7575
Holten7575 Aug. 25 at 8:02 PM
$IFRX nice increase since my early morning rebuy--timed that just in time
1 · Reply
Dotaltevotion
Dotaltevotion Aug. 25 at 7:59 PM
$IFRX whats the catalyst for todays move?
2 · Reply
JerzeyDevil
JerzeyDevil Aug. 25 at 7:52 PM
$IFRX Let’s get an announcement now for FDA emergency use granted, and then have an epic short squeeze. Is that too much to ask? 🤷‍♂️
1 · Reply
Barkingdogs
Barkingdogs Aug. 25 at 7:51 PM
$IFRX what's Izicopan worth?? I know At 5 billion it's $33 🤑🤑🤑
1 · Reply
mconnell
mconnell Aug. 25 at 7:50 PM
0 · Reply
Yoyo35
Yoyo35 Aug. 25 at 7:27 PM
$IFRX It’s nice, but I don’t want to get too optimistic. It’s already happened several times with InflaRx that volume explodes and the stock gains 15% in a day, only for a long slide down and total radio silence to follow.
2 · Reply
MacGyverBud
MacGyverBud Aug. 25 at 7:03 PM
$IFRX Word is getting out. Hard to stop a moving train.
0 · Reply
glup
glup Aug. 25 at 6:53 PM
$IFRX first next target 2.8 ?
1 · Reply
dogDazeSummer
dogDazeSummer Aug. 25 at 6:38 PM
$IFRX important find and nice share. Either way this goes, $AMGN drug has been severely tainted. This clarifies rationality of zek /vilo both being better short , medium & long term options. regardless of FDA pulling, forever inferior, or causing liver toxicity on an ongoing basis- we’re in drivers seat w all star cast of A list shareholders. This new article sites specific evidence that will be harder to overcome. Also cracking through the 200 day moving average and 10% short interest in the float doesn’t hurt. $CCXI got paid $6B for avacopan, ouch! $BIIB paid $2B for pre clinical. $3-$4B is very reasonable given today’s facts.
0 · Reply